Get the Stockscreener App
0.1899
1.20%
-0.0023
After Hours:
.20
0.0101
+5.32%
Kala Bio Inc stock is traded at $0.1899, with a volume of 286.70K.
It is down -1.20% in the last 24 hours and down -63.59% over the past month.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.1922
Open:
$0.199
24h Volume:
286.70K
Relative Volume:
0.43
Market Cap:
$3.67M
Revenue:
$420.00K
Net Income/Loss:
$-19.65M
P/E Ratio:
-0.00137
EPS:
-138.243
Net Cash Flow:
$-26.08M
1W Performance:
-35.40%
1M Performance:
-63.59%
6M Performance:
-98.01%
1Y Performance:
-99.72%
1-Day Range:
$0.1821
$0.1997
1-Week Range:
$0.1146
$0.298
52-Week Range:
$0.1146
$95.50
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1899 | 3.67M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA Bio Inc.: KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - FinanzNachrichten.de
A telehealth platform has generated over $48 million in sales since 2023. KALA Bio may buy it. - Stock Titan
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products - Yahoo Finance
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - kalkine.ca
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - Kalkine
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - Yahoo Finance
Reverse stock split heads to a vote at KALA BIO (NASDAQ: KALA) - Stock Titan
Kala Bio announces annual shareholder meeting - Bitget
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com India
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com UK
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal - TipRanks
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com
KALA BIO, Inc. Enters Exclusive Distribution And Reseller Agreement With Virotek, Inc - marketscreener.com
KALA BIO (NASDAQ: KALA) Announces November 3, 2026 Annual Meeting and September 19 Proposal Deadline - Kalkine Media
KALA BIO Updates Annual Meeting and Proposal Deadlines - TipRanks
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com Nigeria
KALA Stock Update: Exclusive U.S. Distribution Deal with Virotek Highlights Growth Challenges - GuruFocus
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests - Yahoo Finance
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com South Africa
Kala Bio secures exclusive U.S. rights to Virotek genetic tests - Investing.com
Kala Bio and Virotek Finalize Definitive Agreement - GlobeNewswire
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership - finance.yahoo.com
Kala Bio, Virotek enters LOI for distribution agreement - TipRanks
KALA Bio (KALA) Signs Exclusive Distribution LOI with Virotek, F - GuruFocus
Kala Bio, Virotek Outline Exclusive U.S. Genetic Testing | KALA Stock News - Stock Titan
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - TipRanks
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Aimwell Bio pays in shares, not cash, for Trustr technology and begins naming contributors - Stock Titan
KALA (KALA) Close: Ends Down by 2.39% at $0.82 at the Close; Boundary Watch: Traders Can Monitor the $0.78-$0.86 Range in the Latest ReadingLow Vol ETF - vinanet.vn
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Yahoo Finance
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO: Q2 Earnings Snapshot - KTVB
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
K Wave Media Ltd. Announces Pricing of $1.0 Million Registered Direct Offering - Yahoo Finance
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Howard B Rosen | Director |
Mar 12 '26 |
Proposed Sale |
0.29 |
13,576 |
3,975 |
0 |
| CHARLES D MYERS | Director |
Mar 12 '26 |
Proposed Sale |
0.31 |
9,112 |
2,858 |
0 |
| MARY REUMUTH | Officer |
Oct 23 '25 |
Proposed Sale |
0.82 |
967 |
793 |
0 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| MARK IWICKI | Director |
Oct 23 '25 |
Proposed Sale |
0.81 |
154,894 |
125,185 |
0 |
| Iwicki Mark T | Director |
Oct 23 '25 |
Sale |
0.81 |
154,894 |
125,464 |
103,540 |
| TODD M BAZEMORE | Officer |
Oct 22 '25 |
Proposed Sale |
0.83 |
47,768 |
39,686 |
0 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):